Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Paclitaxel/Cisplatin and Adjuvant Chemoradiation for Gastric Cancer
NCT00003298Phase 2Completed
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- Jun 1999
- Primary completion
- Feb 2010
- Modality
- Nanoparticles, Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Paclitaxel Micelles for Injection and Cisplatin micelle injection (HA132) in gastric cancer (GC), sponsored by ECOG-ACRIN Cancer Research Group. Primary endpoint: Grade 3 or Higher Toxicity Incidence on Step 1. Started Jun 1999; status: completed.
02
Drugs
Paclitaxel Micelles for InjectionCisplatin micelle injection (HA132)
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT00003298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003298.